Neurizon Therapeutics Limited has released a press release.
Positive opinion received on OMPD for NUZ-001 in Europe
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust Receives R&D Tax Incentive Rebate
- Appendix 4E and 2024 Annual Report
- Positive Interim Study Results from OLE Study in ALS
- PharmAust Completes Share Purchase Plan
- Monepantel Selected for Entry into HEALEY ALS Platform Trial
Later from Neurizon Therapeutics
- NUZ-001 Reduces Aggregation of Key ALS Disease Target
- Neurizon Presents Positive Preclinical Data on NUZ-001
- Neurizon Receives Additional R&D Tax Incentive Rebate
- Positive 8-month Interim Data from OLE Study
- Neurizon Granted OMPD for NUZ-001 in Europe
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics